Xia Jiasheng – CEO, Guangdong Medical Valley
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
Company information:
Hybribio is a leading provider for in vitro diagnostic assays in Greater China with fully integrated operation chain from R&D, manufacturing, sales & marketing to after-sales technical support service. As of year 2016, over 16 million tests of our HPV Genotyping test has been performed in China. Furthermore, we are the sole company collaborating with the Ministry of Health in Chinese Government to establish the first HPV database system in China. Based on technological platforms such as our proprietary flow-through hybridization technology, real-time PCR technology, and high throughput sequencing, our two major R&D lines – infectious pathogens detection and genetic disease detection – include human papillomavirus (HPV), thalassemia, G6PD, hearing loss susceptibility, phenylketonuria (PKU), and early cancer detection etc. Our products have been widely used in the fields of clinical detection, large scale screening, and prenatal and neonatal management.
Address: 27/F, Bonham Trade Centre, 50 Bonham Strand, Sheung Wan, Hong Kong
Tel.: (+852) 2851 8029
Website: http://hybribio.com/
Email: marketing@hybribio.com
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made…
The Guangzhou production site of HKEX-listed RNA therapeutics biotech Sirnaomics is overseen by pharma industry veteran Edward Wang. Here, Wang explains his contribution to the development of good manufacturing practices…
Lawrence Wong outlines how reproductive medicine-focused Ferring Pharmaceuticals is serving the patients of Hong Kong as the city’s birth rates have plateaued, weighs in on why the establishment of a…
Bio-Gene, part of the Pangenia Group, is one of Hong Kong’s most notable life science success stories, with operations in the laboratory supply of instruments, reagents and consumables. Desmond Hau,…
Dr Brian CHUNG Hon-Yin, Chief Scientific Officer at the Hong Kong Genome Institute (HKGI) and Clinical Associate Professor at the University of Hong Kong (HKU) discusses the creation of the…
Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges…
2023 got off to a good start for Boehringer Ingelheim’s human pharma division. Not only has the year begun with substantial sales growth thanks to the German firm’s diabetes and…
Looking ahead to the Hong Kong International Biotechnology Convention (BIOHK2023) taking place between 13-16 September 2023 at the Hong Kong Convention and Exhibition Centre, three of the event’s leading lights…
Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre’s mainland China arm. Yau explains how the clinical…
MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses…
Executive director & chief strategy officer at HKEX-listed RNA therapeutics biotech Sirnaomics, Dr Dai Xiaochang is no stranger to Hong Kong and mainland China’s pharma and biotech ecosystem, having held…
See our Cookie Privacy Policy Here
